Deutsche Bank Downgrades ABIOMED (ABMD) to Hold
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/3/2026
- Nasdaq ends higher as AI heavyweights rebound ahead of midterm results
- Apple shares slip amid guidance for tightening margins, slowing services growth
- Rising shorts cool U.S. large-cap positioning, cutting liquidation risk: Citi
- Apple's 'unprecedented' memory warning adds fuel to wobbly Micron, SK hynix trade
- Palantir raises 2026 revenue outlook after quarterly revenue nearly doubles on AI
Tweet
Share
E-mailGet Alerts ABMD Hot Sheet
Price: $381.02 --0%
Rating Summary:
7 Buy, 12 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 15 | Down: 22 | New: 15
Rating Summary:
7 Buy, 12 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 15 | Down: 22 | New: 15
Join SI Premium – FREE
Deutsche Bank analyst Pito Chickering downgraded ABIOMED (NASDAQ: ABMD) from Buy to Hold with a price target of $388.00 (from $355.00).
For an analyst ratings summary and ratings history on ABIOMED click here. For more ratings news on ABIOMED click here.
Shares of ABIOMED closed at $377.82 yesterday.
You May Also Be Interested In
- Hagerty Inc. (HGTY) PT Raised to $20 at Oppenheimer
- Vertex (VRTX) PT Raised to $619 at Cantor Fitzgerald
- Shopify (SHOP) PT Lowered to $180 at DA Davidson
Create E-mail Alert Related Categories
Analyst PT Change, DowngradesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
